{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:52:26Z","timestamp":1753890746339,"version":"3.41.2"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T00:00:00Z","timestamp":1731542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Little is known about the changing risk profile of death and conditional survival in patients with operable thyroid cancer. This study aimed to investigate the annual hazard rate of cancer death, actuarial disease-specific survival (DSS), and conditional DSS in patients with thyroid cancer and explore the effects of tumor differentiation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients diagnosed with thyroid cancer (N = 132,354) between 2004 and 2019 were identified from the Surveillance, Epidemiology, and End Results database. The hazard function was used to estimate the annual hazard rate of death. The Kaplan-Meier method and log-rank test were used for the calculation and between-group comparison of actuarial DSS, respectively. The life table was used to estimate the conditional DSS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 1896 (1.4%) patients died due to thyroid cancer during the follow-up period. Patients with ATC (68.9%, 313\/454) were more likely to die than those with PDTC (19.4%, 171\/883) or DTC (1.1%, 1412\/131017). For the entire cohort, patients with DTC and PDTC had excellent and relatively stable one-year conditional survival, respectively; patients with ATC had the worst one-year conditional survival, but they achieved the greatest improvements. The worst one-year conditional survival and the most obvious improvement were seen in patients with ATC regardless of any SEER Summary Stage.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Prognosis improved over time in a tumor differentiation-dependent manner in patients with operable thyroid cancer after diagnosis. This information provides more precise dynamic evaluations of the long-term prognosis of thyroid cancer survivors and paramount clinical implications for individualized treatment and surveillance.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2024.1446312","type":"journal-article","created":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T04:44:34Z","timestamp":1731559474000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Tumor differentiation-dependent conditional survival of patients with operable thyroid cancer"],"prefix":"10.3389","volume":"15","author":[{"given":"Ruo-nan","family":"Yu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zi-qi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui-ling","family":"Qu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-wu","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,11,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2021.0361","article-title":"Sex differences in differentiated thyroid cancer","volume":"32","author":"Shobab","year":"2022","journal-title":"Thyroid"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2021.0662","article-title":"Thyroid cancer incidence and mortality trends in the United States: 2000-2018","volume":"32","author":"Megwalu","year":"2022","journal-title":"Thyroid"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(21)00027-9","article-title":"Thyroid cancer incidence trends by histology in 25 countries: a population-based study","volume":"9","author":"Miranda-Filho","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s12022-022-09707-3","article-title":"Overview of the 2022 WHO classification of thyroid neoplasms","volume":"33","author":"Baloch","year":"2022","journal-title":"Endocr Pathol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/lary.30252","article-title":"Prognostic utility of tumor stage versus american thyroid association risk class in thyroid cancer","volume":"133","author":"Abiri","year":"2023","journal-title":"Laryngoscope"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2018.0128","article-title":"Time-varying pattern of mortality and recurrence from papillary thyroid cancer: lessons from a long-term follow-up","volume":"29","author":"Dong","year":"2019","journal-title":"Thyroid"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e220021","DOI":"10.1530\/ETJ-22-0021","article-title":"Poorly differentiated thyroid carcinoma: a clinician's perspective","volume":"11","author":"Tong","year":"2022","journal-title":"Eur Thyroid J"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2022.0339","article-title":"Conditional survival rate estimates for anaplastic thyroid cancer beyond the first year: an analysis of seer data (2004-2019)","volume":"33","author":"Dong","year":"2023","journal-title":"Thyroid"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s12022-023-09778-w","article-title":"Incidence and clinicopathological features of differentiated high-grade thyroid carcinomas: an institutional experience","volume":"34","author":"Jeong","year":"2023","journal-title":"Endocr Pathol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-2125","article-title":"Getting more out of survival data by using the hazard function","volume":"20","author":"Hess","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28273","article-title":"Dynamic prognostication using conditional survival estimates","volume":"119","author":"Zabor","year":"2013","journal-title":"Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2021.106165","article-title":"Strocss 2021: strengthening the reporting of cohort, cross-sectional and case-control studies in surgery","volume":"96","author":"Mathew","year":"2021","journal-title":"Int J Surg"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.4457","article-title":"Population-based study evaluating and predicting the probability of death resulting from thyroid cancer and other causes among patients with thyroid cancer","volume":"31","author":"Yang","year":"2013","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2022.0700","article-title":"Stage-dependent death hazard and conditional survival of patients with papillary thyroid cancer","volume":"33","author":"Qu","year":"2023","journal-title":"Thyroid"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2015.0316","article-title":"Changes of clinicopathologic characteristics and survival outcomes of anaplastic and poorly differentiated thyroid carcinoma","volume":"26","author":"Lee","year":"2016","journal-title":"Thyroid"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2018.05.009","article-title":"Trends in thyroid cancer: retrospective analysis of incidence and survival in Denmark 1980-2014","volume":"55","author":"Mirian","year":"2018","journal-title":"Cancer Epidemiol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-007-0424-9","article-title":"Conditional survival in gastric cancer: a seer database analysis","volume":"10","author":"Wang","year":"2007","journal-title":"Gastric Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.639839","article-title":"Conditional relative survival of ovarian cancer: a korean national cancer registry study","volume":"11","author":"Shin","year":"2021","journal-title":"Front Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3917","article-title":"Stage-dependent conditional survival and failure hazard of non-metastatic nasopharyngeal carcinoma after intensity-modulated radiation therapy: clinical implications for treatment strategies and surveillance","volume":"10","author":"Wang","year":"2021","journal-title":"Cancer Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.09.050","article-title":"Conditional survival after radical cystectomy for bladder cancer: evidence for a patient changing risk profile over time","volume":"66","author":"Ploussard","year":"2014","journal-title":"Eur Urol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1446312\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T04:44:37Z","timestamp":1731559477000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1446312\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,14]]},"references-count":20,"alternative-id":["10.3389\/fendo.2024.1446312"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2024.1446312","relation":{},"ISSN":["1664-2392"],"issn-type":[{"type":"electronic","value":"1664-2392"}],"subject":[],"published":{"date-parts":[[2024,11,14]]},"article-number":"1446312"}}